NCT05021562 2026-04-13
A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice
Takeda
Completed
Clinical Trials
27 trialsNCT05198804 2026-03-18
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1/2 Completed
NCT06086665 2026-02-04
REFIRM
Asan Medical Center
Completed
NCT04080284 2025-08-19
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
Northwell Health
Phase 2 Completed
NCT03326193 2025-07-31
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Tesaro, Inc.
Phase 2 Completed
NCT03574779 2025-07-15
OPAL
Tesaro, Inc.
Phase 2 Completed
NCT03783949 2025-06-11
EUDARIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT03752216 2024-12-13
NiQoLe
ARCAGY/ GINECO GROUP
Phase 4 Completed
NCT03598270 2024-08-30
ANITA
Grupo Español de Investigación en Cáncer de Ovario
Phase 3 Completed
NCT03154281 2024-08-01
Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast
Avera McKennan Hospital & University Health Center
Phase 1 Completed
NCT03759600 2024-07-16
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
Takeda
Phase 2 Completed
NCT03759587 2024-06-07
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
Takeda
Phase 2 Completed
NCT04284852 2023-12-15
NEOPRIMA
The University of Hong Kong
Phase 2 Completed
NCT03695380 2023-08-14
A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT01847274 2023-06-02
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Tesaro, Inc.
Phase 3 Completed
NCT05751629 2023-04-21
COHORT-A
Tesaro, Inc.
Phase 2 Completed
NCT05734911 2023-02-21
Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study
Zhongda Hospital
Completed
NCT05130515 2023-01-31
CC-ANNIE
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT02657889 2022-12-01
TOPACIO
Tesaro, Inc.
Phase 1/2 Completed
NCT02354586 2022-09-15
QUADRA
Tesaro, Inc.
Phase 2 Completed
NCT02354131 2022-08-30
AVANOVA
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 1/2 Completed
NCT04392102 2022-08-29
A Study of Niraparib in Patients With Relapsed Ovarian Cancer
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT04546373 2021-08-05
Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Grupo Español de Investigación en Cáncer de Ovario
Completed
NCT03359850 2021-05-28
Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients
Tesaro, Inc.
Phase 1 Completed
NCT04785716 2021-03-08
Real-life Use of Niraparib in a Patient Access Program in Norway
Oslo University Hospital
Completed
NCT03551171 2019-01-24
The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer
Zai Lab (Hong Kong), Ltd.
Phase 1 Completed
NCT00749502 2013-07-25
A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)
Tesaro, Inc.
Phase 1 Completed